- Home
- NKTR vs HCM Comparison
NKTR vs HCM Comparison
Compare NKTR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NKTR | HCM |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | HCM |
|---|---|---|
| Price | $71.44 | $10.71 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $146.67 | $13.75 |
| AVG Volume (30 Days) | ★ 833.2K | 46.6K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,711,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $21.02 | $9.77 |
| 52 Week High | $109.00 | $18.17 |
Technical Indicators
Market Signals| Indicator | NKTR | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 54.73 |
| Support Level | $64.28 | $10.83 |
| Resistance Level | $76.78 | $11.80 |
| Average True Range (ATR) | 3.57 | 0.21 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 66.12 | 58.33 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.